MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.

摘要

Relapsed/refractory multiple myeloma (MM) constitutes a specific and unmet medical need. Although the advent of novel therapies, targeting disease biology and tumor microenvironment, has significantly improved the median survival for patients with advanced disease, prognosis remains poor. Prior to the development of novel biologically based therapies for MM, relapses after successive treatment regimens resulted in progressively shorter response durations, which typically reflected the occurrence of drug resistance, as well as changes in disease parameters, with tumor cells expressing more aggressive phenotypes, higher proliferative fractions and lower apoptotic rates. Although several prognostic factors have been identified for newly diagnosed myeloma, factors that retain prognostic value in the context of relapsed/refractory disease remained undefined [1, 2].